# A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)

> **NCT02835105** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Clostridium Difficile Associated Diarrhea (CDAD)

## Interventions

- **DRUG:** Surotomycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02835105
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835105, "A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02835105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*